Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2300070888Phase 4Not yet recruiting
Phase 4, randomised trial in hepatic neoplasm comparing Intrathecal hydromorphone 75 μg with Intrathecal morphine 150 μg (2 arms). Primary endpoint: VAS pain score. Planned start Apr 2023; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2300070888.